$500.00 - $900.00
Min. Order : 25 Kilograms

EP9/BP2017 CAS 21187-98-4 Gliclazide

Get Latest Price
Trade Assurance
Built-in order protection service in alibaba.com
Product quality
On-time shipment
More on shipping and other trade services.

Quick Details

Port: Shanghai/Beijing
Payment Terms: L/C,T/T
Supply Ability: 10 Ton/Tons per Month
Brand Name: SINOWAY
Other Names: ---
Type: Endocrine System Agents
Place of Origin: Fujian China
EINECS No.: --
Grade Standard: Medicine Grade
Purity: 99%min
MF: C15H21N3O3S
Model Number: EP/USP
Appearance: White crystalline power
CAS No.: 21187-98-4
Packaging Detail: 25KG/DRUM
Sinoway Industrial Co., Ltd.
Supplier
CN
Trading Company
87.5%
Response Rate
90.9%
On-time delivery rate
US$ 290,000+
41
Transactions
11-50
Employees
5-10
R&D staffs
0
Patents
Visit Store
Product Description

Test

Requirement

Result

Appearance

White or almost white powder

White powder

Identification/IR

Corresponding to reference spectrum

Corresponding to reference spectrum

                   Related  substances

Impurity F

≤0.1%

0.02%

Unspecified impurities

≤0.10%

0.04%

Sum of impurities other than F

≤0.2%

0.04%

Impurity B

≤2ppm

0.4ppm

Heavy metals

≤10ppm

<10ppm

Loss on drying

≤0.25%

0.12%

Sulphated ash

≤0.1%

<0.05%

Assay (dried substance)

99.0~101.0%

99.2%

CONCLUSION

            CONFORM WITH BP2017.

Usage:

Gliclazide is the second generation oral sulphonylurea hypoglycemic agent, which has a stronger effect. Its mechanism is similar to tolbutamide, that is, it selectively acts on islet β cells, promotes insulin secretion, and improves insulin after glucose intake. freed. Its role is more than 10 times stronger than tolbutamide. In recent years, it has also been found that gliclazide has an extrapancreatic effect, which enhances the effect of peripheral tissues on insulin. It may be the result of enhanced biological effects after insulin receptors. At the same time, hepatic glucose production and output are also resisted, so that gliclazide has a post-pancreatic receptor or receptor. Another view is that sulfonylureas increase the number of insulin receptors in target tissues and increase the sensitivity of peripheral target tissues to insulin. Glieszide has been proven to reduce platelet aggregation and adhesion by animal experiments and clinical use, and prevent the deposition of the albumin on the microvascular wall, which has a preventive and therapeutic effect on diabetic microangiopathy. Animal experiments have shown that long-term use of gliclazide can significantly reduce liver cholesterol, lower triacylglycerols and fatty acids. Histological examinations show that it can resist the damage of arteries, especially coronary arteries, caused by high cholesterol foods, and it is beneficial to reduce the cardiovascular complications of diabetes

termplatetermplatetermplate

 
Contact Us
termplate

Sinoway Industrial Co., Ltd.

Welcome to visit us

Exhibition 2018:

CPhI Japan (Tokyo)   Booth No. R16

CPhI China (Shanghai)

                                 Booth No. E1E01

CPhI Worldwide (Spain Madrid)

                                 Booth No. 5B42

Learn us more

www.china-sinoway.com

www.sinowaychem.com